ArticleFrontiers in immunology2020
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses.Signal transduction and targeted therapy · 2026Review
- Combined innate immune cell therapy, tumor-specific antibody, and radiation prompt antitumor response in pancreatic cancer models.Science advances · 2025Article
- Article
- Therapeutic In Situ Cancer Vaccine Using Pulsed Stereotactic Body Radiotherapy-A Translational Model.Vaccines · 2023Article
- Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment.Cancer immunology, immunotherapy : CII · 2023Article
- Anti-tumor antibody isotype response can be modified with locally administered immunoadjuvants.Drug delivery and translational research · 2023Article
- Antibody landscape of C57BL/6 mice cured of B78 melanoma via immunotherapy.bioRxiv : the preprint server for biology · 2023Article
- Antibody landscape of C57BL/6 mice cured of B78 melanoma via a combined radiation and immunocytokine immunotherapy regimen.Frontiers in immunology · 2023Article
- Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization.Journal for immunotherapy of cancer · 2022Article
- The present and future of immunocytokines for cancer treatment.Cellular and molecular life sciences : CMLS · 2022Review
- Interleukin-12 as an in situ cancer vaccine component: a review.Cancer immunology, immunotherapy : CII · 2022Review
- Short-course neoadjuvant in situ vaccination for murine melanoma.Journal for immunotherapy of cancer · 2022Article
- Histotripsy Ablation Alters the Tumor Microenvironment and Promotes Immune System Activation in a Subcutaneous Model of Pancreatic Cancer.IEEE transactions on ultrasonics, ferroelectrics, and frequency control · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Claire C BanielDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Clinton M HeinzeDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Anna HoefgesDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Elizabeth G SumiecDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Jaquelyn A HankDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Peter M CarlsonDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Won Jong JinDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Ravi B PatelDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Raghava N SriramaneniDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Stephen D GilliesProvenance Biopharmaceuticals, Carlisle, MA, United States.
Amy K ErbeDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Ciara N SchwarzDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Alexander A PieperDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Alexander L RakhmilevichDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Paul M SondelDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
Zachary S MorrisDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States.
University of Wisconsin–Madison · US
Funding
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6MUniversity of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9MUnderstanding and Overcoming Resistance to Immunotherapies in Childhood CancersU54CA232568 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · PI MACKALL, CRYSTAL, MARIS, JOHN M · 2018 to 2022
$13.1MINTEGRATED TRAINING FOR PHYSICIAN-SCIENTISTST32GM008692 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BURKARD, MARK E · 1998 to 2020
$10.3MNRSA Training CoreTL1TR002375 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Vivek Prabhakaran · 2017 to 2026
$8.4MIntegrated Training For Physician-ScientistsT32GM140935 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anna Huttenlocher, Jeniel E Nett · 2021 to 2026
$6.5MEnhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4MImmunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality ImmunotherapiesU01CA233102 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT, WEICHERT, JAMEY P · 2018 to 2022
$4.0MCombining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor VaccinationDP5OD024576 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI MORRIS, ZACHARY SCOTT · 2017 to 2021
$1.9MMolecular targeted radiotherapy to overcome resistance to in situ cancer vaccinationF30CA228315 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI CARLSON, PETER M · 2019 to 2021
$102kNCATS NIH HHS TL1 TR002375NCATS NIH HHS UL1 TR002373NCI NIH HHS F30 CA228315NCI NIH HHS P30 CA014520NCI NIH HHS R35 CA197078NCI NIH HHS U01 CA233102NCI NIH HHS U54 CA232568NIGMS NIH HHS T32 GM008692NIGMS NIH HHS T32 GM140935NIH HHS DP5 OD024576
Abstract
In a syngeneic murine melanoma (MEL) model, we recently reported an
Indexed as
AnimalsAntigens, NeoplasmAntineoplastic Agents, ImmunologicalBiomarkers, TumorB-LymphocytesCancer VaccinesCell Line, TumorCombined Modality TherapyDisease Models, AnimalImmune Checkpoint InhibitorsImmune Checkpoint ProteinsImmunity, HumoralImmunologic MemoryImmunomodulationImmunophenotypingLung NeoplasmsAntigens, NeoplasmAntineoplastic Agents, ImmunologicalBiomarkers, TumorCancer VaccinesImmune Checkpoint InhibitorsImmune Checkpoint ProteinsVaccinesadaptive immunityendogenous antibodieshumoral memorymelanomaradiationvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.